Graphite One

BioTech Stocks

Company
Last Trade
Change
Volume
Shares Out
Market Cap
NASDAQ REGN REGENERON PHARMACEUTICALS
US$ 843.60
-79.19 -8.58
1.07M
108.42M
US$ 91.460B
Follow
NASDAQ BNTX BIONTECH
US$ 111.48
-2.46 -2.16
940,302
237.77M
US$ 26.510B
Follow
NASDAQ MRNA MODERNA
US$ 54.63
-0.09 -0.16
4.75M
384.40M
US$ 21.000B
Follow
NASDAQ ROIV ROIVANT SCIENCES
US$ 11.68
-0.10 -0.85
3.78M
739.52M
US$ 8.640B
Follow
NASDAQ NUVL NUVALENT
US$ 89.22
-1.02 -1.13
747,038
65.11M
US$ 5.810B
Follow
NASDAQ KRYS KRYSTAL BIOTECH
US$ 176.39
0.86 0.49
287,475
28.73M
US$ 5.070B
Follow
NASDAQ BBIO BRIDGEBIO PHARMA
US$ 25.48
1.69 7.10
1.93M
188.03M
US$ 4.790B
Follow
NASDAQ ACLX ARCELLX
US$ 86.17
-0.64 -0.74
492,488
53.76M
US$ 4.630B
Follow
NASDAQ MRUS MERUS
US$ 50.30
-0.98 -1.91
466,639
68.21M
US$ 3.430B
Follow
NASDAQ EWTX EDGEWISE THERAPEUTICS
US$ 34.00
0.68 2.04
431,248
93.77M
US$ 3.190B
Follow
NASDAQ KYMR KYMERA THERAPEUTICS
US$ 46.47
-1.20 -2.52
432,274
64.58M
US$ 3.000B
Follow
NASDAQ VERA VERA THERAPEUTICS
US$ 43.82
3.18 7.82
1.35M
54.83M
US$ 2.400B
Follow
NASDAQ BLTE BELITE BIO
US$ 69.90
9.35 15.44
133,696
30.61M
US$ 2.140B
Follow
NASDAQ LBPH LONGBOARD PHARMACEUTICALS
US$ 59.69
-0.01 -0.02
883,886
34.29M
US$ 2.050B
Follow
NASDAQ CNTA CENTESSA PHARMACEUTICALS
US$ 15.67
0.58 3.84
314,740
113.31M
US$ 1.780B
Follow
NASDAQ RXRX RECURSION PHARMACEUTICALS
US$ 6.40
-0.28 -4.19
3.52M
275.07M
US$ 1.760B
Follow
NASDAQ CERT CERTARA
US$ 10.25
-0.06 -0.58
692,861
160.89M
US$ 1.650B
Follow
NASDAQ SAVA CASSAVA SCIENCES
US$ 26.21
0.21 0.81
1.38M
47.98M
US$ 1.260B
Follow
NASDAQ EQRX EQRX
US$ 2.34
0.00 0.00
0
487.70M
US$ 1.140B
Follow
NASDAQ BCYC BICYCLE THERAPEUTICS
US$ 22.71
-1.32 -5.49
471,558
47.50M
US$ 1.080B
Follow
NASDAQ SANA SANA BIOTECHNOLOGY
US$ 3.66
0.00 0.00
1.29M
222.47M
US$ 814.240M
Follow
NASDAQ ABCL ABCELLERA BIOLOGICS
US$ 2.73
-0.05 -1.80
1.24M
294.67M
US$ 804.450M
Follow
NASDAQ ICVX ICOSAVAX
US$ 15.31
0.00 0.00
0
50.23M
US$ 769.020M
Follow
NYSE NUVB NUVATION BIO
US$ 2.30
-0.04 -1.71
1.09M
333.78M
US$ 767.690M
Follow
NASDAQ HUMA HUMACYTE
US$ 5.39
0.24 4.66
3.18M
119.35M
US$ 643.300M
Follow
NASDAQ TERN TERNS PHARMACEUTICALS
US$ 6.94
0.05 0.73
858,435
84.44M
US$ 586.010M
Follow
NASDAQ AVXL ANAVEX LIFE SCIENCES
US$ 6.84
1.12 19.61
2.00M
84.80M
US$ 579.610M
Follow
OTCMKTS ELTP ELITE PHARMACEUTICALS
US$ 0.50
0.05 11.24
808,331
1.07B
US$ 529.650M
Follow
NASDAQ ABSI ABSCI
US$ 3.92
-0.22 -5.31
1.03M
113.56M
US$ 445.160M
Follow
NASDAQ CDXC CHROMADEX
US$ 5.86
2.28 63.69
37.41M
75.93M
US$ 444.950M
Follow
NASDAQ LXRX LEXICON PHARMACEUTICALS
US$ 1.22
-0.73 -37.44
20.91M
361.49M
US$ 441.020M
Follow
NASDAQ CMPS COMPASS PATHWAYS
US$ 6.03
0.00 0.00
0
68.39M
US$ 412.390M
Follow
NASDAQ ESPR ESPERION THERAPEUTICS
US$ 2.03
-0.10 -4.69
2.14M
196.22M
US$ 398.330M
Follow
NASDAQ AMLX AMYLYX PHARMACEUTICALS
US$ 5.64
0.37 7.02
1.27M
68.08M
US$ 383.970M
Follow
NYSE DNA GINKGO BIOWORKS
US$ 7.75
-0.09 -1.15
424,110
43.10M
US$ 334.020M
Follow
OTCMKTS NWBO NORTHWEST BIOTHERAPEUTICS
US$ 0.26
-0.0091 -3.35
1.14M
1.25B
US$ 328.620M
Follow
NASDAQ BMEA BIOMEA FUSION
US$ 9.04
-1.30 -12.57
1.27M
36.21M
US$ 327.340M
Follow
NASDAQ DSGN DESIGN THERAPEUTICS
US$ 5.20
-0.37 -6.64
66,888
56.62M
US$ 294.420M
Follow
NASDAQ NKTX NKARTA
US$ 3.19
-0.14 -4.20
490,679
70.56M
US$ 225.090M
Follow
NASDAQ PEPG PEPGEN
US$ 6.48
-0.59 -8.35
33,351
32.59M
US$ 211.180M
Follow
NASDAQ CRBP CORBUS PHARMACEUTICALS
US$ 16.92
0.35 2.11
248,002
12.04M
US$ 203.720M
Follow
NASDAQ PROK PROKIDNEY
US$ 1.55
-0.13 -7.74
380,222
126.05M
US$ 195.380M
Follow
NASDAQ GRPH GRAPHITE BIO
US$ 3.18
0.00 0.00
0
58.24M
US$ 185.200M
Follow
OTCMKTS SKYE SKYE BIOSCIENCE
US$ 5.56
0.32 6.11
92,515
30.34M
US$ 168.690M
Follow
NASDAQ GALT GALECTIN THERAPEUTICS
US$ 2.50
-0.02 -0.79
108,712
62.28M
US$ 155.700M
Follow
NASDAQ TNYA TENAYA THERAPEUTICS
US$ 1.94
-0.11 -5.37
469,261
78.89M
US$ 153.050M
Follow
NASDAQ ACRS ACLARIS THERAPEUTICS
US$ 2.09
0.29 16.11
1.26M
71.34M
US$ 149.100M
Follow
NASDAQ ADAG ADAGENE
US$ 3.00
-0.15 -4.76
26,921
44.27M
US$ 132.810M
Follow
OTCMKTS NGENF NERVGEN PHARMA
US$ 1.88
0.15 8.67
5,300
70.18M
US$ 131.940M
Follow
NASDAQ CRDL CARDIOL THERAPEUTICS
US$ 1.87
0.05 2.75
253,728
69.88M
US$ 130.680M
Follow
NASDAQ DBTX DECIBEL THERAPEUTICS
US$ 4.91
0.00 0.00
0
25.13M
US$ 123.390M
Follow
NASDAQ BIOR BIORA THERAPEUTICS
US$ 3.35
-0.13 -3.75
27,372
36.47M
US$ 122.150M
Follow
NYSEAMEX ZOM ZOMEDICA
US$ 0.12
-0.0006 -0.50
2.75M
997.95M
US$ 119.950M
Follow
NASDAQ NVCT NUVECTIS PHARMA
US$ 6.41
-1.48 -18.76
203,622
18.65M
US$ 119.550M
Follow
NYSE ANVS ANNOVIS BIO
US$ 9.09
-0.46 -4.82
142,855
13.05M
US$ 118.620M
Follow
NASDAQ TALS TALARIS THERAPEUTICS
US$ 2.72
0.00 0.00
0
42.81M
US$ 116.440M
Follow
NASDAQ IVVD INVIVYD
US$ 0.91
0.0035 0.38
405,967
119.44M
US$ 109.120M
Follow
NASDAQ RGC REGENCELL BIOSCIENCE
US$ 8.09
1.18 17.08
277,080
13.01M
US$ 105.250M
Follow
NASDAQ HLVX HILLEVAX
US$ 1.87
0.03 1.63
127,361
49.78M
US$ 93.090M
Follow
NASDAQ IKNA IKENA ONCOLOGY
US$ 1.72
0.02 1.18
22,731
48.26M
US$ 83.010M
Follow
NASDAQ LABP LANDOS BIOPHARMA
US$ 22.93
0.00 0.00
0
3.13M
US$ 71.770M
Follow
NASDAQ RANI RANI THERAPEUTICS
US$ 2.31
-0.01 -0.43
431,715
29.29M
US$ 67.660M
Follow
NASDAQ QNCX QUINCE THERAPEUTICS
US$ 1.54
0.23 17.56
603,204
43.28M
US$ 66.650M
Follow
NASDAQ OMGA OMEGA THERAPEUTICS
US$ 1.11
-0.16 -12.60
244,617
55.16M
US$ 61.230M
Follow
NASDAQ RPHM RENEO PHARMACEUTICALS
US$ 1.82
0.00 0.00
0
33.43M
US$ 60.840M
Follow
OTCMKTS ACOGF ALPHA COGNITION
US$ 0.40
-0.008 -1.99
15,004
150.86M
US$ 59.590M
Follow
NASDAQ GANX GAIN THERAPEUTICS
US$ 2.32
0.14 6.42
350,895
25.54M
US$ 59.250M
Follow
NASDAQ IMRX IMMUNEERING
US$ 1.87
-0.05 -2.60
151,602
29.65M
US$ 55.450M
Follow
NASDAQ VOR VOR BIOPHARMA
US$ 0.80
0.0064 0.80
443,860
68.40M
US$ 55.050M
Follow
NASDAQ LVTX LAVA THERAPEUTICS
US$ 1.90
-0.02 -1.04
74,699
26.30M
US$ 49.970M
Follow
NASDAQ AADI AADI BIOSCIENCE
US$ 1.99
0.03 1.53
24,982
24.61M
US$ 48.970M
Follow
NASDAQ AGLE AEGLEA BIOTHERAPEUTICS
US$ 12.01
0.00 0.00
0
4.05M
US$ 48.640M
Follow
NASDAQ ANEB ANEBULO PHARMACEUTICALS
US$ 1.84
-0.01 -0.54
539
25.93M
US$ 47.710M
Follow
NASDAQ IXHL INCANNEX HEALTHCARE
US$ 2.59
0.32 14.10
140,162
17.64M
US$ 45.690M
Follow
NASDAQ IMMX IMMIX BIOPHARMA
US$ 1.59
-0.06 -3.64
29,360
27.45M
US$ 43.650M
Follow
NASDAQ RLYB RALLYBIO
US$ 1.01
-0.01 -0.98
71,419
41.49M
US$ 41.900M
Follow
OTCMKTS MEDXF MEDEXUS PHARMACEUTICALS
US$ 1.70
0.00 0.00
0
24.53M
US$ 41.700M
Follow
NASDAQ HOOK HOOKIPA PHARMA
US$ 3.84
-0.02 -0.52
38,090
9.66M
US$ 37.090M
Follow
NASDAQ LEXX LEXARIA BIOSCIENCE
US$ 2.32
0.05 2.20
119,734
15.81M
US$ 36.680M
Follow
NASDAQ BNGO BIONANO GENOMICS
US$ 0.42
0.00 0.00
0
86.00M
US$ 36.160M
Follow
NASDAQ PMN PROMIS NEUROSCIENCES
US$ 1.15
0.06 5.50
107,601
29.89M
US$ 34.370M
Follow
NASDAQ VTVT VTV THERAPEUTICS
US$ 13.93
0.00 0.00
0
2.43M
US$ 33.850M
Follow
NASDAQ OMIC SINGULAR GENOMICS SYSTEMS
US$ 13.46
0.46 3.54
10,165
2.50M
US$ 33.650M
Follow
NASDAQ RAIN RAIN ONCOLOGY
US$ 1.21
0.00 0.00
0
27.58M
US$ 33.370M
Follow
NASDAQ DYAI DYADIC INTERNATIONAL
US$ 1.06
0.01 0.95
4,913
29.48M
US$ 31.250M
Follow
NASDAQ ANGN ANGION BIOMEDICA
US$ 1.00
0.00 0.00
0
30.11M
US$ 30.110M
Follow
NASDAQ LSTA LISATA THERAPEUTICS
US$ 3.16
0.35 12.46
60,646
8.32M
US$ 26.290M
Follow
NASDAQ LGVN LONGEVERON
US$ 2.03
-0.13 -6.02
372,308
12.88M
US$ 26.150M
Follow
NASDAQ PLUR PLUR
US$ 4.85
0.04 0.83
25,297
5.39M
US$ 26.140M
Follow
NASDAQ BOLT BOLT BIOTHERAPEUTICS
US$ 0.66
-0.49 -42.74
22,963
38.26M
US$ 25.190M
Follow
NASDAQ RNXT RENOVORX
US$ 1.02
0.02 2.00
4,345
23.99M
US$ 24.470M
Follow
NASDAQ BCTX BRIACELL THERAPEUTICS
US$ 0.79
0.02 3.20
331,876
30.71M
US$ 24.400M
Follow
OTCMKTS DTCFF DEFENCE THERAPEUTICS
US$ 0.46
0.00 0.00
0
45.54M
US$ 20.920M
Follow
NASDAQ SEEL SEELOS THERAPEUTICS
US$ 2.91
0.00 0.00
0
6.98M
US$ 20.310M
Follow
NASDAQ CMMB CHEMOMAB THERAPEUTICS
US$ 1.38
-0.04 -2.82
34,801
14.36M
US$ 19.820M
Follow
NASDAQ FNCH FINCH THERAPEUTICS
US$ 11.85
10.05 558.33
1,807
1.61M
US$ 19.080M
Follow
NASDAQ BIAF BIOAFFINITY TECHNOLOGIES
US$ 1.37
0.00 0.00
76,501
13.49M
US$ 18.480M
Follow
NASDAQ AMRS AMYRIS
US$ 0.05
0.00 0.00
0
369.39M
US$ 18.470M
Follow
NASDAQ LHDX LUCIRA HEALTH
US$ 0.45
0.00 0.00
0
40.60M
US$ 18.270M
Follow
NYSEAMEX NHWK NIGHTHAWK BIOSCIENCES
US$ 0.41
0.00 0.00
0
36.03M
US$ 14.900M
Follow
NASDAQ TNXP TONIX PHARMACEUTICALS
US$ 0.14
-0.02 -9.78
11.39M
103.12M
US$ 14.360M
Follow
NASDAQ IMNN IMUNON
US$ 0.95
-0.0099 -1.03
75,919
14.40M
US$ 13.680M
Follow
OTCMKTS OTLC ONCOTELIC THERAPEUTICS
US$ 0.03
0.00 0.00
10,800
406.27M
US$ 13.410M
Follow
NASDAQ INAB IN8BIO
US$ 0.29
0.02 6.03
189,434
46.79M
US$ 13.400M
Follow
NASDAQ ICU SEASTAR MEDICAL
US$ 3.03
-0.23 -7.06
207,748
4.19M
US$ 12.700M
Follow
NASDAQ SNSE SENSEI BIOTHERAPEUTICS
US$ 0.49
-0.08 -14.18
537,828
25.15M
US$ 12.330M
Follow
NASDAQ KTRA KINTARA THERAPEUTICS
US$ 0.22
0.00 0.00
0
55.37M
US$ 11.930M
Follow
NASDAQ JAGX JAGUAR HEALTH
US$ 1.29
0.00 0.00
0
9.24M
US$ 11.920M
Follow
NASDAQ IPA IMMUNOPRECISE ANTIBODIES
US$ 0.42
-0.07 -14.27
367,503
27.92M
US$ 11.660M
Follow
OTCMKTS VPHIF VALEO PHARMA
US$ 0.12
0.00 0.00
0
98.66M
US$ 11.650M
Follow
NASDAQ AYTU AYTU BIOSCIENCE
US$ 1.94
-0.05 -2.64
9,051
5.97M
US$ 11.570M
Follow
OTCMKTS NBIO NASCENT BIOTECH
US$ 0.06
-0.01 -14.00
60,300
172.20M
US$ 11.110M
Follow
NASDAQ MDNA MEDICENNA THERAPEUTICS
US$ 0.16
0.00 0.00
0
69.64M
US$ 10.930M
Follow
OTCMKTS TBRIF THERMA BRIGHT
US$ 0.02
-0.0002 -0.80
19,000
438.08M
US$ 10.860M
Follow
NASDAQ KPRX KIORA PHARMACEUTICALS
US$ 3.60
-0.10 -2.70
25,033
2.97M
US$ 10.690M
Follow
NASDAQ RDHL REDHILL BIOPHARMA
US$ 8.17
-0.17 -2.04
11,045
1.28M
US$ 10.460M
Follow
NASDAQ EDSA EDESA BIOTECH
US$ 3.20
-0.20 -5.88
404,430
3.25M
US$ 10.400M
Follow
NASDAQ SNTI SENTI BIOSCIENCES
US$ 2.18
0.02 0.93
6,557
4.58M
US$ 9.980M
Follow
NASDAQ MBIO MUSTANG BIO
US$ 0.27
-0.04 -13.42
682,991
36.39M
US$ 9.720M
Follow
NASDAQ VRAX VIRAX BIOLABS
US$ 2.04
-0.20 -8.93
173,460
4.34M
US$ 8.850M
Follow
NASDAQ GLTO GALECTO
US$ 6.75
-0.56 -7.66
15,991
1.25M
US$ 8.440M
Follow
NASDAQ CHEK CHECK-CAP
US$ 1.43
0.00 0.00
0
5.85M
US$ 8.380M
Follow
NASDAQ RNAZ TRANSCODE THERAPEUTICS
US$ 0.48
-0.02 -4.76
178,056
17.27M
US$ 8.290M
Follow
NASDAQ COEP COEPTIS THERAPEUTICS
US$ 0.20
-0.01 -5.22
262,380
39.72M
US$ 7.860M
Follow
OTCMKTS HYEX HEALTHY EXTRACTS
US$ 2.60
0.00 0.00
0
2.99M
US$ 7.770M
Follow
OTCMKTS SZLSF STAGEZERO LIFE SCIENCES
US$ 0.06
0.00 0.00
0
123.53M
US$ 7.470M
Follow
NASDAQ UPC UNIVERSE PHARMACEUTICALS
US$ 0.28
0.0045 1.65
605,014
23.65M
US$ 6.550M
Follow
NASDAQ XBIO XENETIC BIOSCIENCES
US$ 4.10
-0.18 -4.21
36,586
1.54M
US$ 6.310M
Follow
OTCMKTS VYYRF VOYAGEUR PHARMACEUTICALS
US$ 0.05
0.00 0.00
0
139.47M
US$ 6.280M
Follow
NASDAQ CDIO CARDIO DIAGNOSTICS
US$ 0.26
0.0073 2.89
2.85M
24.08M
US$ 6.260M
Follow
OTCMKTS SIGY SIGYN THERAPEUTICS
US$ 4.75
0.00 0.00
0
1.26M
US$ 5.980M
Follow
OTCMKTS TDSGF TELO GENOMICS
US$ 0.08
0.00 0.00
0
74.56M
US$ 5.980M
Follow
NASDAQ PRTG PORTAGE BIOTECH
US$ 5.58
0.03 0.54
36,563
1.05M
US$ 5.860M
Follow
NASDAQ IMPL IMPEL PHARMACEUTICALS
US$ 0.24
0.00 0.00
0
23.90M
US$ 5.760M
Follow
NASDAQ ENSC ENSYSCE BIOSCIENCES
US$ 0.65
0.01 1.83
142.61M
8.82M
US$ 5.730M
Follow
NASDAQ ERNA ETERNA THERAPEUTICS
US$ 1.04
-0.06 -5.45
4,344
5.41M
US$ 5.630M
Follow
OTCMKTS TRYPF TRYP THERAPEUTICS
US$ 0.06
0.00 0.00
0
96.42M
US$ 5.420M
Follow
NASDAQ CMND CLEARMIND MEDICINE
US$ 1.36
-0.10 -6.85
63,649
3.98M
US$ 5.410M
Follow
OTCMKTS CELZ CREATIVE MEDICAL TECHNOLOGY HOLDINGS
US$ 4.02
-0.12 -2.90
50,882
1.34M
US$ 5.390M
Follow
NYSEAMEX TOVX THERIVA BIOLOGICS
US$ 1.99
0.51 34.46
85.12M
2.27M
US$ 4.520M
Follow
NASDAQ FRTX FRESH TRACKS THERAPEUTICS
US$ 0.73
-0.06 -7.59
10
5.97M
US$ 4.360M
Follow
NASDAQ VIRI VIRIOS THERAPEUTICS
US$ 0.16
0.00 0.00
0
27.76M
US$ 4.300M
Follow
NASDAQ HGEN HUMANIGEN
US$ 0.04
0.00 0.00
0
119.08M
US$ 4.300M
Follow
NASDAQ XRTX XORTX THERAPEUTICS
US$ 1.43
-0.05 -3.38
11,739
2.90M
US$ 4.150M
Follow
NASDAQ KTTA PASITHEA THERAPEUTICS
US$ 3.80
-0.15 -3.80
21,327
1.04M
US$ 3.950M
Follow
NASDAQ SHPH SHUTTLE PHARMACEUTICALS
US$ 1.67
-0.13 -7.22
274,734
2.23M
US$ 3.720M
Follow
NASDAQ SBFM SUNSHINE BIOPHARMA
US$ 2.84
-0.01 -0.35
52,369
1.22M
US$ 3.460M
Follow
NASDAQ PALI PALISADE BIO
US$ 2.77
-0.33 -10.65
112,632
1.18M
US$ 3.270M
Follow
OTCMKTS BICX BIOCOR RX
US$ 0.30
0.00 0.00
0
10.89M
US$ 3.270M
Follow
OTCMKTS APLIF APPILI THERAPEUTICS
US$ 0.03
0.00 0.00
140,000
121.27M
US$ 3.070M
Follow
NASDAQ CFRX CONTRAFECT
US$ 0.23
0.00 0.00
0
10.70M
US$ 2.480M
Follow
NASDAQ BPTS BIOPHYTIS
US$ 8.22
0.00 0.00
0
286,504
US$ 2.360M
Follow
OTCMKTS RVVTF REVIVE THERAPEUTICS
US$ 0.0062
0.00 0.00
58,150
358.45M
US$ 2.220M
Follow
OTCMKTS LOBEF LOBE SCIENCES
US$ 0.01
0.00 0.00
0
171.56M
US$ 2.060M
Follow
OTCMKTS AVRW AVENIR WELLNESS
US$ 0.02
0.001 5.00
200
77.99M
US$ 1.640M
Follow
OTCMKTS MYNDF MYND LIFE SCIENCES
US$ 0.03
0.00 0.00
0
47.82M
US$ 1.430M
Follow
OTCMKTS ODYY ODYSSEY GROUP
US$ 0.01
0.00 0.00
0
96.36M
US$ 1.350M
Follow
OTCMKTS AGNPF ALGERNON PHARMACEUTICALS
US$ 0.05
0.00 0.00
0
27.30M
US$ 1.310M
Follow
NASDAQ PXMD PAXMEDICA
US$ 0.10
-0.59 -85.40
5,202
12.20M
US$ 1.230M
Follow
OTCMKTS AQSZF AEQUUS PHARMACEUTICALS
US$ 0.0084
0.00 0.00
0
132.63M
US$ 1.110M
Follow
OTCMKTS NMLSF NOVA MENTIS LIFE SCIENCES
US$ 0.0055
0.0015 37.50
17,704
148.32M
US$ 816K
Follow
OTCMKTS PRXTF PURE EXTRACTS
US$ 0.0054
0.00 0.00
0
116.77M
US$ 631K
Follow
NASDAQ NEXI NEXIMMUNE
US$ 0.22
0.01 5.29
1,954
1.39M
US$ 307K
Follow
OTCMKTS TRMNF NEW WAVE HOLDINGS
US$ 0.008
0.00 0.00
0
35.87M
US$ 287K
Follow
NASDAQ HUGE FSD PHARMA
US$ 0.09
0.00 0.00
0
708,609
US$ 64K
Follow
OTCMKTS BIOAF BIOASIS TECHNOLOGIES
US$ 0.0001
0.00 0.00
0
79.41M
US$ 8K
Follow
NASDAQ EVLO EVELO BIOSCIENCES
US$ 0.0004
-0.32 -99.87
25
18.98M
US$ 8K
Follow
NASDAQ CMRA COMERA LIFE SCIENCES
US$ 0.0001
0.00 0.00
0
30.74M
US$ 3K
Follow
NASDAQ EFTR EFFECTOR THERAPEUTICS
US$ 0.0003
0.00 0.00
0
4.70M
US$ 1K
Follow
OTCMKTS GDBYF GOODBODY HEALTH
US$ 0.00001
0.00 0.00
0
36.50M
US$ 365
Follow
NASDAQ ALTS ALT5 SIGMA
US$ 1.71
0.00 0.00
0
-
US$ -
Follow

BioTech News

Green Stock News

Record Monthly Enrollment Achieved in SeaStar Medical’s Pivotal Adult AKI Trial

November 1, 2024

DENVER, Nov. 01, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, reports setting a new monthly enrollment record with 10 critically ill acute kidney injury (AKI) patients added to the NEUTRALIZE-AKI pivotal trial during the past month,... Read more

Green Stock News

Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress-Europe 2024

November 1, 2024

New data show tolerability and no evidence of spreading to blood or tissues even at high doses of Tonix’s attenuated live-virus, minimally replicating vaccine candidate TNX-801 in immunocompromised animals TNX-801, has characteristics that align closely with the World Health Organization’s (WHO) preferred target product profile (TPP) criteria for mpox vaccines WHO-declared public health emergency... Read more

Green Stock News

Galecto Reports Third Quarter 2024 Financial Results

November 1, 2024

Completed strategic review to focus on oncology and severe liver diseases Announced acquisition of global rights to BRM-1420, a dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of AML from Bridge Medicines Appointed Dr. Amy Wechsler to the Board of Directors and Matthew Kronmiller as Executive Vice President of Strategy and Chief Business Officer BOSTON, Nov. 01, 2024 (GLOBE... Read more

Green Stock News

Lexicon Pharmaceuticals Announces Outcome of FDA Advisory Committee for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney...

October 31, 2024

THE WOODLANDS, Texas, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the outcome of the U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Meeting to review the company’s New Drug Application (NDA) for Zynquista (sotagliflozin), an oral SGLT1/SGLT2 inhibitor, as an adjunct to insulin therapy for glycemic... Read more

Green Stock News

Absci and Twist Bioscience Collaborate to Design Novel Antibody using Generative AI

October 31, 2024

VANCOUVER, Wash. and SOUTH SAN FRANCISCO, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI) a data-first generative AI drug creation company, and Twist Bioscience Corporation (NASDAQ: TWST) a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today unveiled a collaboration to design a novel therapeutic using... Read more

Green Stock News

SeaStar Medical Adds Second Hospital Customer for QUELIMMUNE

October 31, 2024

DENVER, Oct. 31, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, has shipped QUELIMMUNE™ directly to a second hospital customer. QUELIMMUNE is the Company’s Selective Cytopheretic Device (SCD) for treating critically ill children... Read more

Green Stock News

Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis

October 31, 2024

Targeted, better-tolerated oral PDE4 inhibitors are an unmet need in inflammatory bowel disease (IBD) PALI-2108 demonstrates in ex vivo studies; targeted activation and reduced side effects, potentially enhancing patient compliance compared to existing PDE4 inhibitors Data presented at the American College of Gastroenterology’s (ACG) 2024 Annual Scientific Meeting Carlsbad, CA, Oct.... Read more

Green Stock News

Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission

October 31, 2024

Demonstrated safety and efficacy across multiple Phase 2 and Phase 3 studies Appili provides update on Aditxt transaction and encourages shareholders to vote their shares as soon as possible for the November 6, 2024 shareholders meeting HALIFAX, Nova Scotia, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical... Read more

Green Stock News

Anavex Life Sciences Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer’s Trial: Data Presented at CTAD Conference 2024

October 31, 2024

Data of Blarcamesine confirm upstream SIGMAR1 activation Presented as Late Breaking Oral Communications at Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2024 Oral, once daily blarcamesine meaningfully slowed clinical decline for early Alzheimer's disease patients with good comparative safety profile and no associated neuroimaging adverse events NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE)... Read more

Green Stock News

Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure

October 31, 2024

TORONTO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures, announced today an update on the research study evaluating Bucillamine as a potential treatment for nerve agent... Read more

Green Stock News

Regeneron Pharmaceuticals Reports Third Quarter 2024 Financial and Operating Results

October 31, 2024

Third quarter 2024 revenues increased 11% to $3.72 billion versus third quarter 2023 Third quarter 2024 Dupixent® global net sales (recorded by Sanofi) increased 23% to $3.82 billion versus third quarter 2023 Third quarter 2024 U.S. net sales for EYLEA HD® and EYLEA® increased 3% versus third quarter 2023 to $1.54 billion, including $392 million from EYLEA HD Third quarter... Read more

Green Stock News

Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update

October 31, 2024

Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L and petosemtamab monotherapy in 2/3L r/m HNSCC enrolling Petosemtamab in 2L+ r/m HNSCC interim clinical data accepted for rapid oral presentation at ESMO® Asia Congress 2024 Based on the Company’s current operating plan, existing cash, cash equivalents, and marketable securities expected to fund Merus’... Read more

Green Stock News

Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results

October 31, 2024

Presented updated clinical results across oncology pipeline, including a 45% overall response rate (ORR) for zelenectide pevedotin monotherapy and a 45% ORR for BT5528 6.5 mg/m2 every two weeks monotherapy, both in metastatic urothelial cancer Progressed radiopharmaceuticals pipeline with first human imaging data validating the potential of MT1-MMP as a novel cancer target and outlined company strategy... Read more

Green Stock News

Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update

October 31, 2024

KT-621 (STAT6) IND cleared by FDA and dosing in the Phase 1 clinical trial initiated, with data expected in the first half of 2025 Sanofi expanding KT-474/SAR444656 (IRAK4) Phase 2 clinical trials in HS and AD to dose ranging Phase 2b studies to accelerate overall development timelines; completion of both expanded trials expected by mid-2026 KT-295, a new TYK2 degrader, selected as the development... Read more

Green Stock News

Compass Pathways Announces Third Quarter 2024 Financial Results and Business Updates

October 31, 2024

Top-line COMP005 data for COMP360 phase 3 pivotal program in treatment-resistant depression now expected in second quarter 2025 COMP006 data will now be announced after 26-week time point, expected in the second half of 2026 Strategic reorganization to focus all efforts on COMP360 program resulting in reduction of workforce of approximately 30% Cash position of $207 million Conference call October... Read more

Green Stock News

ChromaDex Reports Third Quarter 2024 Financial Results

October 31, 2024

Total net sales of $25.6 million, up $6.1 million or 31% year-over-year, gross margin of 63.5% and record net income and adjusted EBITDA of $1.9 million and $2.9 million, respectively, for the three months ended September 30, 2024 LOS ANGELES / Oct 31, 2024 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the third quarter of 2024. Third Quarter 2024 Financial... Read more

Green Stock News

Bionano Genomics Announces $3 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

October 31, 2024

SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it has entered into a definitive agreement with certain institutional investors for the purchase and sale of an aggregate of 9,881,113 shares of its common stock and Series C warrants to purchase up to an aggregate of 9,881,113 shares of common stock and short-term Series D warrants to purchase... Read more

Green Stock News

Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist...

October 30, 2024

Preclinical data from ex vivo human islet experiments showed that icovamenib (BMF-219) was able to enhance the activity of glucagon-like peptide-1 (GLP-1)-based therapies, potentially leading to increased insulin secretion and improved glycemic control in patients with diabetes Phase II study (COVALENT-211), combining icovamenib with a GLP-1-based therapy, planned to begin in 2025 BMF-650, an... Read more

Green Stock News

HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer

October 30, 2024

Study done in collaboration with Memorial Sloan Kettering and led by Dr. Winston Wong, Head and Neck Oncologist and Dr. Alan Ho, Chief of the Head and Neck Oncology Service IIT will evaluate eseba-vec in patients who are HPV16+ after treatment for curative intent Potential to expand the eseba-vec HNSCC opportunity into adjuvant care Initial safety and efficacy data from IIT expected in 2026 NEW... Read more

Green Stock News

bioAffinity Technologies Announces Award of Japanese Patent for CyPath® Lung

October 30, 2024

SAN ANTONIO / Oct 30, 2024 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage lung cancer and other lung diseases, today announced that the Japan Patent Office has issued a Certificate of Grant of Patent to bioAffinity Technologies for the method of predicting the likelihood of lung... Read more

Green Stock News

Telo Genomics Expands its Strategic Collaboration with Mayo Clinic

October 30, 2024

Toronto, Ontario--(Newsfile Corp. - October 30, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, is pleased to announce that it has amended its agreement with Mayo Clinic, Rochester, Minnesota, US.... Read more

Green Stock News

ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer’s Disease Conference

October 30, 2024

Results indicated PMN310 was generally well-tolerated and monthly dosing can provide CSF levels adequate for target engagement\ Initiation of Phase 1b clinical trial in Alzheimer’s disease patients planned for year-end 2024 CAMBRIDGE, Massachusetts and TORONTO, Ontario, Oct. 30, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation... Read more

Green Stock News

IMUNON to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting

October 30, 2024

Results from OVATION 2 Study of IMNN-001 to be highlighted in late-breaking acceptance Company also announces FDA End-of-Phase 2 in-person meeting to discuss Phase 3 trial of IMNN-001 Phase 3 trial is expected to begin in Q1 2025 LAWRENCEVILLE, N.J., Oct. 30, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated imm... Read more

Green Stock News

ALT5 Sigma Announces Participation at the Spartan Capital Investor Conference

October 30, 2024

Premier Event to Showcase Growth Companies and Foster High-Level Investor Engagement LAS VEGAS, NV / ACCESSWIRE / October 30, 2024 / ALT5 Sigma Corporation (NASDAQ:ALTS), is proud to announce its participation in Spartan Capital Securities, LLC's inaugural investor conference on November 4th at the prestigious Pierre Hotel in New York. This participation aligns with our commitment to engage... Read more

Green Stock News

Rallybio Announces Approval of Clinical Trial Applications for Phase 2 Trial of RLYB212 in Pregnant Women at Higher Risk of Alloimmunization and FNAIT

October 29, 2024

First Ever Trial in Pregnant Women at Higher Risk of Alloimmunization and FNAIT  Screening in the Phase 2 Clinical Trial On Track to Initiate in 4Q 2024  NEW HAVEN, Conn. / Oct 29, 2024 / Business Wire / Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases,... Read more

Green Stock News

Shuttle Pharmaceuticals Pharma Doses First Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

October 29, 2024

GAITHERSBURG, Md., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), announced today that the first three patients in its Phase 2 Clinical Trial of Ropidoxuridine for the treatment of... Read more

Green Stock News

Kiora Pharmaceuticals Receives Investigational New Drug Approval to Initiate ABACUS-2, a Phase 2 Clinical Trial of KIO-301 for the Treatment of Retinitis Pigmentosa

October 29, 2024

Encinitas, California--(Newsfile Corp. - October 29, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced it received regulatory approval to initiate a Phase 2 clinical trial to investigate KIO-301 for vision restoration in patients with retinitis pigmentosa. The ABACUS-2 trial will be a 36 patient, multi-center, double-masked, randomized, controlled, multiple... Read more

Green Stock News

Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA™ (pemivibart) Provided Substantial Protection from Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No...

October 29, 2024

Following strong protection (84% relative risk reduction versus placebo) demonstrated through month 6 with pemivibart, CANOPY clinical trial participants were followed for an additional six-month period (months 7-12), with no additional doses, to assess safety and efficacy as drug concentrations declined over time In the six-month off-drug follow-up period (months 7-12), substantially reduced... Read more

Green Stock News

Longeveron® Presents Lomecel-B™ Data for Alzheimer’s Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24)

October 29, 2024

Findings offer potential mechanistic and clinical insights in the development of cellular therapy Lomecel-B™ for mild Alzheimer’s disease (AD) Lomecel-B™ capacity to inhibit MMP14 correlates with improved clinical and biomarker outcomes in mild AD Immunomodulatory and pro-vascular effects of Lomecel-B™ in mild AD potentially driven by ability to exert MMP14 inhibition which... Read more

Green Stock News

Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights

October 29, 2024

U.S. Food and Drug Administration (FDA) lifted Clinical Hold on COVALENT-111 (Type 2 Diabetes) & COVALENT-112 (Type 1 Diabetes) trials COVALENT-111 Phase 2b 26-week topline data of the dose expansion cohorts expected in December 2024 COVALENT-112 Phase 2a 26-week topline data of the open label portion expected in December 2024 On track to announce our third clinical candidate, BMF-650, for... Read more

COPYRIGHT ©2022 GREEN STOCK NEWS

Research Tools
Stock News
Popular Topics
Miscellaneous